Kura Oncology (NASDAQ:KURA) Shares Down 7.6% – Should You Sell?

Kura Oncology, Inc. (NASDAQ:KURA) dropped 7.6% during trading on Monday . The stock traded as low as $6.56 and last traded at $6.52. Approximately 240,598 shares were traded during trading, a decline of 78% from the average daily volume of 1,089,767 shares. The stock had previously closed at $7.05.

Wall Street Analysts Forecast Growth

KURA has been the subject of several recent research reports. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. JMP Securities reiterated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a research note on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Finally, UBS Group lowered their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Stock Down 6.3 %

The company has a market cap of $533.39 million, a P/E ratio of -2.79 and a beta of 0.85. The stock has a 50-day moving average of $7.82 and a two-hundred day moving average of $11.94. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Kura Oncology by 14.6% in the fourth quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock valued at $41,973,000 after acquiring an additional 615,211 shares in the last quarter. RA Capital Management L.P. bought a new position in Kura Oncology in the fourth quarter worth $38,769,000. Millennium Management LLC lifted its position in Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after buying an additional 1,521,954 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after buying an additional 41,535 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Kura Oncology by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after buying an additional 23,113 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.